ORGO Stock Analysis: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$2.43
0.00 (0.00%)
▲
5d:
+0.83%
30d:
-8.65%
90d:
-1.62%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ORGO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ORGO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $2.43, which is considered fair relative to its 30-day fair value range of $2.35 to $2.58. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.8) compared to its historical average (18.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ORGO is in a strong downtrend. Immediate support is located at $2.31, while resistance sits at $2.58.
Market Sentiment: ORGO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.00 (+23.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORGO is in a strong downtrend. Immediate support is located at $2.31, while resistance sits at $2.58.
Market Sentiment: ORGO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.00 (+23.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.35 -
$2.58
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.5% below Wall St target ($3.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.35 -
$2.58
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.34
(14.1%)
Support & Resistance Levels
Support Level
$2.31
Resistance Level
$2.58
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.84
Wall Street Target
$3.00
(+23.5%)
Revenue Growth (YoY)
-57.1%
Earnings Growth (YoY)
555.2%
Profit Margin
0.5%
PE vs Historical
-8.8 vs 18.1
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 11:36 PM ET
Data refreshes hourly during market hours. Next update: 12:36 AM
Data refreshes hourly during market hours. Next update: 12:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Arthur S Leibowitz
BUY
5000 shares
2026-03-09
Michael Joseph Driscoll
BUY
10000 shares
2026-03-09
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
